Diagnosis and management of pulmonary veno-occlusive disease

References

• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;43(38):3618–3731. doi: 10.1183/13993003.00879-2022
   Google Scholar
• Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2000;162(5):1964–1973. doi: 10.1164/ajrccm.162.5.9912045
   PubMed Web of Science ®Google Scholar
• Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2009;33(1):189–200. doi: 10.1183/09031936.00090608
   PubMed Web of Science ®Google Scholar
• Frazier AA, Franks TJ, Mohammed T-L, et al. From the archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. RadioGraphics. 2007;27(3):867–882. doi: 10.1148/rg.273065194
   PubMed Web of Science ®Google Scholar
• Lantuéjoul S, Sheppard MN, Corrin B, et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol. 2006;30(7):850–857. doi: 10.1097/01.pas.0000209834.69972.e5
   PubMed Web of Science ®Google Scholar
• Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation. 2017;136(21):2022–2033. doi: 10.1161/CIRCULATIONAHA.117.028351
   PubMed Web of Science ®Google Scholar
• Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87(4):220–233. doi: 10.1097/MD.0b013e31818193bb
   PubMed Web of Science ®Google Scholar
• Holcomb Jr BW, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest. 2000;118(6):1671–1679. doi: 10.1378/chest.67.4.487
   PubMed Web of Science ®Google Scholar
• Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518–1534. doi: 10.1183/13993003.00026-2016
   PubMed Web of Science ®Google Scholar
• Montani D, Lau EM, Descatha A, et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J. 2015;46(6):1721–1731. doi: 10.1183/13993003.00814-2015
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137(2):376–387. doi: 10.1378/chest.09-1140
   PubMed Web of Science ®Google Scholar
• Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46(1):65–69. doi: 10.1038/ng.2844
   PubMed Web of Science ®Google Scholar
• Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest. 2014;145(2):231–236. doi: 10.1378/chest.13-2366
   PubMed Web of Science ®Google Scholar
• Girerd B, Montani D, Jaïs X, et al. Genetic counselling in a national referral centre for pulmonary hypertension. Eur Respir J. 2016;47(2):541–552. doi: 10.1183/13993003.00717-2015
   PubMed Web of Science ®Google Scholar
• Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801899. doi: 10.1183/13993003.01899-2018
   PubMed Web of Science ®Google Scholar
• Montani D, Girerd B, Jaïs X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med. 2017;5(2):125–134. doi: 10.1016/S2213-2600(16)30438-6
   PubMed Web of Science ®Google Scholar
• Lechartier B, Girerd B, Eyries M, et al. Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers. Eur Respir J. 2022;60(2):2200760. doi: 10.1183/13993003.00760-2022
   PubMed Web of Science ®Google Scholar
• Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol. 2004;183(1):65–70. doi: 10.2214/ajr.183.1.1830065
   PubMed Web of Science ®Google Scholar
• Ranchoux B, Günther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356–371. doi: 10.1016/j.ajpath.2014.10.021
   PubMed Web of Science ®Google Scholar
• Morse CC, Sigler C, Lock S, et al. Pulmonary toxicity of cyclophosphamide: a 1-year study. Exp Mol Pathol. 1985;42(2):251–260. doi: 10.1016/0014-4800(85)90031-0
   PubMed Web of Science ®Google Scholar
• Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58(2):521–531. doi: 10.1002/art.23303
   PubMed Web of Science ®Google Scholar
• Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130(1):182–189. doi: 10.1378/chest.130.1.182
   PubMed Web of Science ®Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137. doi: 10.1161/CIRCULATIONAHA.111.079921
   PubMed Web of Science ®Google Scholar
• Perros F, Günther S, Ranchoux B, et al. Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models. Circulation. 2015;132(9):834–847. doi: 10.1161/CIRCULATIONAHA.115.014207
   PubMed Web of Science ®Google Scholar
• Certain M-C, Chaumais M-C, Jaïs X, et al. Characteristics and long-term outcomes of pulmonary venoocclusive disease induced by Mitomycin C. Chest. 2021;159(3):1197–1207. doi: 10.1016/j.chest.2020.09.238
   PubMed Web of Science ®Google Scholar
• Hackman RC, Madtes DK, Petersen FB, et al. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation. 1989;47(6):989–992. doi: 10.1097/00007890-198906000-00014
   PubMed Web of Science ®Google Scholar
• Steward CG, Pellier I, Mahajan A, et al. Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol. 2004;124(1):63–71. doi: 10.1046/j.1365-2141.2003.04739.x
   PubMed Web of Science ®Google Scholar
• Caliez J, Riou M, Manaud G, et al. Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. Pulm Circ. 2020;10(4):1–4. doi: 10.1177/2045894020907884
   Web of Science ®Google Scholar
• Rounds S, Lu Q. Cigarette smoke alters lung vascular permeability and endothelial barrier function (2017 grover conference series). Pulm Circ. 2018;8(3):1–10. doi: 10.1177/2045894018794000
   Web of Science ®Google Scholar
• Burton VJ, Ciuclan LI, Holmes AM, et al. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood. 2011;117(1):333–341. doi: 10.1182/blood-2010-05-285973
   PubMed Web of Science ®Google Scholar
• Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014;129(12):1332–1340. doi: 10.1161/CIRCULATIONAHA.113.004555
   PubMed Web of Science ®Google Scholar
• Schiess R, Senn O, Fischler M, et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest. 2010;138(5):1086–1092. doi: 10.1378/chest.09-2962
   PubMed Web of Science ®Google Scholar
• Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007;38(6):893–902. doi: 10.1016/j.humpath.2006.11.022
   PubMed Web of Science ®Google Scholar
• Johnson SR, Patsios D, Hwang DM, et al. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol. 2006;33:2347–2350.
   PubMed Web of Science ®Google Scholar
• Dorfmüller P, Montani D, Humbert M. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J. 2010;35(1):6–8. doi: 10.1183/09031936.00081009
   PubMed Web of Science ®Google Scholar
• Iwaki M, Imaizumi K, Yokoi T, et al. Idiopathic pulmonary veno-occlusive disease. Intern Med Tokyo Jpn. 2009;48(15):1289–1292. doi: 10.2169/internalmedicine.48.1935
   Google Scholar
• Montani D, Kemp K, Dorfmuller P, et al. Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med. 2009;30(4):411–420. doi: 10.1055/s-0029-1233310
   PubMed Web of Science ®Google Scholar
• Tada H, Konno T, Aizu M, et al. Pulmonary hypertension associated with veno-occlusive disease in systemic sclerosis: insight into the mechanism of resistance to vasodilator. J Cardiol Cases. 2012;5(1):e44–e47. doi: 10.1016/j.jccase.2011.11.001
   PubMedGoogle Scholar
• Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis. 1986;134(4):809–811. doi: 10.1164/arrd.1986.134.4.809
   PubMedGoogle Scholar
• Hamada K, Teramoto S, Narita N, et al. Pulmonary veno-occlusive disease in pulmonary Langerhans′ cell granulomatosis. Eur Respir J. 2000;15(2):421–423. doi: 10.1034/j.1399-3003.2000.15b33.x
   PubMed Web of Science ®Google Scholar
• Kokturk N, Demir N, Demircan S, et al. Pulmonary veno-occlusive disease in a patient with a history of Hashimoto’s thyroiditis. Indian J Chest Dis Allied Sci. 2005;47(4):289–292.
   PubMedGoogle Scholar
• Kay D, Kadri F, Fitzpatrick G, et al. Anti-synthetase syndrome-associated pulmonary veno-occlusive disease. Pulm Circ. 2020;10(3):1–4. doi: 10.1177/2045894020935289
   Web of Science ®Google Scholar
• Ghigna M-R, Guignabert C, Montani D, et al. BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J. 2016;48(6):1668–1681. doi: 10.1183/13993003.00464-2016
   PubMed Web of Science ®Google Scholar
• Nossent EJ, Antigny F, Montani D, et al. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2018;37:647–655. doi: 10.1016/j.healun.2017.09.022
   PubMed Web of Science ®Google Scholar
• Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958;18(4):533–547. doi: 10.1161/01.CIR.18.4.533
   PubMed Web of Science ®Google Scholar
• Cool CD, Kennedy D, Voelkel NF, et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997;28(4):434–442. doi: 10.1016/S0046-8177(97)90032-0
   PubMed Web of Science ®Google Scholar
• Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J. 2009;34(2):371–379. doi: 10.1183/09031936.00106008
   PubMed Web of Science ®Google Scholar
• Thomas de Montpréville V, Dulmet E, Fadel E, et al. Lymph node pathology in pulmonary veno-occlusive disease and pulmonary capillary heamangiomatosis. Virchows Arch Int J Pathol. 2008;453(2):171–176. doi: 10.1007/s00428-008-0636-3
   PubMed Web of Science ®Google Scholar
• Montani D, Dorfmüller P, Girerd B, et al. Natural history over 8 years of pulmonary vascular disease in a patient carrying biallelic EIF2AK4 mutations. Am J Respir Crit Care Med. 2018;198(4):537–541. doi: 10.1164/rccm.201802-0317LE
   PubMed Web of Science ®Google Scholar
• Rambihar VS, Fallen EL, Cairns JA. Pulmonary veno-occlusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings. Can Med Assoc J. 1979;120(12):1519–1522.
   PubMed Web of Science ®Google Scholar
• McGoon M, Gutterman D, Steen V, et al. American college of chest physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1):14S–34S. doi: 10.1378/chest.126.1_suppl.14S
   PubMed Web of Science ®Google Scholar
• Heath D, Segel N, Bishop J. Pulmonary veno-occlusive disease. Circulation. 1966;34(2):242–248. doi: 10.1161/01.CIR.34.2.242
   PubMed Web of Science ®Google Scholar
• François CJ, Schiebler ML. Imaging of pulmonary hypertension. Radiol Clin North Am. 2016;54(6):1133–1149. doi: 10.1016/j.rcl.2016.05.011
   PubMed Web of Science ®Google Scholar
• Peacock A, Naeije R, Rubin LJ. Pulmonary Circulation: diseases and their treatment. 3rd ed. London: CRC Press; 2011. doi: 10.1201/b13219
   Google Scholar
• Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15):1898–1907. doi: 10.1093/eurheartj/ehq170
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111. doi: 10.1161/CIRCULATIONAHA.104.488486
   PubMed Web of Science ®Google Scholar
• Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998;113(1):237–240. doi: 10.1378/chest.113.1.237
   PubMed Web of Science ®Google Scholar
• Bailey CL, Channick RN, Auger WR, et al. “High probability” perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med. 2000;162(5):1974–1978. doi: 10.1164/ajrccm.162.5.2003045
   PubMed Web of Science ®Google Scholar
• Lefebvre B, Kyheng M, Giordano J, et al. Dual-energy CT lung perfusion characteristics in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PVOD/PCH): preliminary experience in 63 patients. Eur Radiol. 2022;32(7):4574–4586. doi: 10.1007/s00330-022-08577-x
   PubMed Web of Science ®Google Scholar
• Carmona S, Loureiro MJ, Santos J, et al. Lung ventilation/perfusion scintigraphy in pulmonary capillary hemangiomatosis: a pattern to consider. Rev Esp Med Nucl Imagen Mol. 2013;32(2):98–101. doi: 10.1016/j.remn.2012.06.009
   PubMed Web of Science ®Google Scholar
• Günther S, Jaïs X, Maitre S, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum. 2012;64(9):2995–3005. doi: 10.1002/art.34501
   PubMedGoogle Scholar
• Seferian A, Helal B, Jaïs X, et al. Ventilation/Perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J. 2012;40(1):75–83. doi: 10.1183/09031936.00097911
   PubMed Web of Science ®Google Scholar
• Rich S, Pietra GG, Kieras K, et al. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med. 1986;105(4):499–502. doi: 10.7326/0003-4819-105-4-499
   PubMed Web of Science ®Google Scholar
• Godinas L, Amar D, Montani D, et al. Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2016;35(5):647–656. doi: 10.1016/j.healun.2015.12.022
   PubMed Web of Science ®Google Scholar
• Rabiller A, Jaïs X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. European Respiratory Journal. 2006;27(1):108–113. doi: 10.1183/09031936.06.00054105
   PubMed Web of Science ®Google Scholar
• Ogawa A, Takahashi Y, Matsubara H. Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. J Cardiol. 2018;72(3):255–260. doi: 10.1016/j.jjcc.2018.02.009
   PubMed Web of Science ®Google Scholar
• Pérez-Olivares C, Segura de la Cal T, Flox-Camacho Á, et al. The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. Eur Respir J. 2021;57:2100115. doi: 10.1183/13993003.00115-2021
   PubMed Web of Science ®Google Scholar
• Laveneziana P, Montani D, Dorfmüller P, et al. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. Eur Respir J. 2014;44(4):1069–1072. doi: 10.1183/09031936.00088914
   PubMed Web of Science ®Google Scholar
• Lederer H, Muggli B, Speich R, et al. Haemosiderin-laden sputum macrophages for diagnosis in pulmonary veno-occlusive disease. Plos One. 2014;9(12):e115219. doi: 10.1371/journal.pone.0115219
   PubMed Web of Science ®Google Scholar
• Montani D, Girerd B, Jaïs X, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J. 2021;58(1):2004229. doi: 10.1183/13993003.04229-2020
   PubMed Web of Science ®Google Scholar
• Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–783. doi: 10.1097/00007890-198712000-00011
   PubMed Web of Science ®Google Scholar
• McDonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1):116–122. doi: 10.1002/hep.1840040121
   PubMed Web of Science ®Google Scholar
• Vion A-C, Rautou P-E, Durand F, et al. Interplay of inflammation and endothelial dysfunction in bone marrow transplantation: focus on Hepatic veno-occlusive disease. Semin Thromb Hemost. 2015;41(6):629–643. doi: 10.1055/s-0035-1556728
   PubMed Web of Science ®Google Scholar
• Sato Y, Asada Y, Hara S, et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology. 1999;34(1):66–70. doi: 10.1046/j.1365-2559.1999.00569.x
   PubMed Web of Science ®Google Scholar
• Günther S, Perros F, Rautou P-E, et al. Understanding the similarities and differences between Hepatic and pulmonary veno-occlusive disease. Am J Pathol. 2019;189(6):1159–1175. doi: 10.1016/j.ajpath.2019.02.007
   PubMed Web of Science ®Google Scholar
• Dignan FL, Wynn RF, Hadzic N, et al. Haemato-oncology task force of British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444–457.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–1665. doi: 10.1182/blood-2015-10-676924
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet Lond Engl. 2012;379:1301–1309. doi: 10.1016/S0140-6736(11)61938-7
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916. doi: 10.1183/13993003.01916-2018
   PubMed Web of Science ®Google Scholar
• Del Cerro Marín MJ, Sabaté Rotés A, Rodriguez Ogando A, et al. REHIPED investigators. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit Care Med. 2014;190(12):1421–1429. doi: 10.1164/rccm.201406-1052OC
   PubMed Web of Science ®Google Scholar
• van Loon RLE, Roofthooft MTR, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755–1764. doi: 10.1161/CIRCULATIONAHA.110.969584
   PubMed Web of Science ®Google Scholar
• Berger RMF, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet Lond Engl. 2012;379:537–546. doi: 10.1016/S0140-6736(11)61621-8
   PubMed Web of Science ®Google Scholar
• Levy M, Eyries M, Szezepanski I, et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J. 2016;48(4):1118–1126. doi: 10.1183/13993003.00211-2016
   PubMed Web of Science ®Google Scholar
• Cruz-Utrilla A, Gallego-Zazo N, Tenorio-Castaño JA, et al. Clinical Implications of the genetic background in pediatric pulmonary arterial hypertension: data from the Spanish REHIPED registry. IJMS. 2022;23(18):10433. doi: 10.3390/ijms231810433
   Google Scholar
• Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, et al. The genetic Epidemiology of pediatric pulmonary arterial hypertension. J Pediatr. 2020;225:65–73.e5. doi: 10.1016/j.jpeds.2020.05.051
   PubMed Web of Science ®Google Scholar
• Lerner-Ellis JP, Anastasio N, Liu J, et al. Spectrum of mutations in MMACHC , allelic expression, and evidence for genotypeâ??phenotype correlations. Hum Mutat. 2009;30(7):1072–1081. doi: 10.1002/humu.21001
   PubMed Web of Science ®Google Scholar
• Kömhoff M, Roofthooft MT, Westra D, et al. Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics. 2013;132(2):e540–544. doi: 10.1542/peds.2012-2581
   PubMed Web of Science ®Google Scholar
• Berteloot L, Proisy M, Jais J-P, et al. Idiopathic, heritable and veno-occlusive pulmonary arterial hypertension in childhood: computed tomography angiography features in the initial assessment of the disease. Pediatr Radiol. 2019;49(5):575–585. doi: 10.1007/s00247-018-04331-y
   PubMed Web of Science ®Google Scholar
• Trobaugh-Lotrario AD, Greffe B, Deterding R, et al. Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol. 2003;25(5):405–409. doi: 10.1097/00043426-200305000-00011
   PubMed Web of Science ®Google Scholar
• Isshiki K, Shima H, Yamazaki F, et al. A case of pulmonary veno-occlusive disease following Hepatic veno-occlusive disease after autologous hematopoietic stem cell transplantation for neuroblastoma. J Pediatr Hematol Oncol. 2020;42(7):e677–e679. doi: 10.1097/MPH.0000000000001566
   PubMed Web of Science ®Google Scholar
• Allewelt H, Martin PL, Szabolcs P, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: single institution experience. Pediatr Blood Cancer. 2015;62(12):2216–2222. doi: 10.1002/pbc.25711
   PubMed Web of Science ®Google Scholar
• Kawashima N, Ikoma M, Sekiya Y, et al. Successful treatment of pulmonary hypertension with beraprost and sildenafil after cord blood transplantation for infantile leukemia. Int J Hematol. 2013;97(1):147–150. doi: 10.1007/s12185-012-1246-z
   PubMed Web of Science ®Google Scholar
• Blanc J, Vouhé P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med. 2004;350(6):623. doi: 10.1056/NEJM200402053500623
   PubMed Web of Science ®Google Scholar
• Grady RM, Canter MW, Wan F, et al. International registry Potts shunt. Pulmonary-to-systemic arterial shunt to treat children with severe pulmonary hypertension. J Am Coll Cardiol. 2021;78(5):468–477. doi: 10.1016/j.jacc.2021.05.039
   PubMed Web of Science ®Google Scholar
• Wille KM, Sharma NS, Kulkarni T, et al. Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation. Ann Am Thorac Soc. 2014;11(9):1411–1418. doi: 10.1513/AnnalsATS.201408-354OC
   PubMedGoogle Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–163. doi: 10.1161/CIRCULATIONAHA.109.911818
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142(2):448–456. doi: 10.1378/chest.11-1460
   PubMed Web of Science ®Google Scholar
• Ogawa A, Satoh T, Tamura Y, et al. Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am J Cardiol. 2017;119(9):1479–1484. doi: 10.1016/j.amjcard.2017.01.015
   PubMed Web of Science ®Google Scholar
• Montani D, Jaïs X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J. 2009;34(6):1348–1356. doi: 10.1183/09031936.00017809
   PubMed Web of Science ®Google Scholar
• Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J Off J Jpn Circ Soc. 2012;76(7):1729–1736. doi: 10.1253/circj.CJ-11-0973
   PubMed Web of Science ®Google Scholar
• Salzman GA, Rosa UW. Prolonged survival in pulmonary veno-occlusive disease treated with nifedipine. Chest. 1989;95(5):1154–1156. doi: 10.1378/chest.95.5.1154
   PubMed Web of Science ®Google Scholar
• Sourla E, Paspala A, Boutou A, et al. A case of pulmonary veno-occlusive disease: diagnostic dilemmas and therapeutic challenges. Ther Adv Respir Dis. 2013;7(2):119–123. doi: 10.1177/1753465812468042
   PubMed Web of Science ®Google Scholar
• Humbert M, Maître S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med. 1998;157(5):1681–1685. doi: 10.1164/ajrccm.157.5.9708065
   PubMed Web of Science ®Google Scholar
• Perros F, Cohen-Kaminsky S, Gambaryan N, et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2013;187(2):189–196. doi: 10.1164/rccm.201208-1364OC
   PubMed Web of Science ®Google Scholar
• Corrin B, Spencer H, Turner-Warwick M, et al. Pulmonary veno-occlusion–an immune complex disease? Virchows Arch A Pathol Anat Histol. 1974;364(1):81–91. doi: 10.1007/BF01230859
   PubMed Web of Science ®Google Scholar
• Bergbaum C, Samaranayake CB, Pitcher A, et al. A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression? Eur Respir J. 2021;57(6):2004354. doi: 10.1183/13993003.04354-2020
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Bunpo P, Cundiff JK, et al. The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. American Journal Of Physiology-Endocrinology And Metabolism. 2013;305(9):E1124–1133. doi: 10.1152/ajpendo.00080.2013
   PubMed Web of Science ®Google Scholar
• Ogawa A, Miyaji K, Matsubara H. Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Respir med. 2017;131:215–219. doi: 10.1016/j.rmed.2017.08.032
   PubMed Web of Science ®Google Scholar
• Izbicki G, Shitrit D, Schechtman I et al. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation. J Heart Lung Transplant. 2005 May 1;24(5):635–637. doi:10.1016/j.healun.2004.02.008
   PubMed Web of Science ®Google Scholar